About / News
On mobile devices, tap the image to read the article.
January 16, 2023
Biogenity and TAmiRNA, an Austrian biotech company specializing in transcriptomics, has entered into a partnership to enable Multi-omics workflows combining Proteomics and Transcriptomics. Kenneth Kastaniegaard, CEO of Biogenity, commented:"TAmiRNA is a well-established player in the field of transcriptomics, with a focus on using microRNA (miRNA) as diagnostic and therapeutic targets. Combining this data with proteomics can bring essential insight into molecular signals and the biological response they cause."
January 10, 2023
We are seeking a team member to join us on a journey to support scientists from various industries, including pharmaceutical, biotech, food technology, and academia, in their omics research projects. In our fast-growing company, we are seeking a highly skilled and motivated individual to join our team in supporting researchers with a range of omics projects, including proteomics, metabolomics, transcriptomics, and multiomics. The ideal candidate will have a strong interest in omics and a passion for sales and customer service.
March 23, 2022
At Biogenity, we are happy to announce that the Innovation Fund Denmark has agreed to invest in Biogenity's Innobooster-project: "Signal Pathway Intelligent Characterization (BioSWITCH)." BioSWITCH will be a series of algorithms to track molecular signals in expression-based omics data. One of the biggest problems in omics studies is the complexity, especially in multi-omics studies when discovering new diagnostics, prognostics, and therapeutics targets.
June 01, 2021
At Biogenity, we are very proud to be able to facilitate your proteomics project using Mass Spectrometry. Since we have not posted on our proteomics workflow, we thought it would be obvious to present the whole customer journey, highlighting how to support your next project from sample to biology.